Shooting an arrow against convulsion: Novel modified flavonolignan derivatives as carbonic anhydrase II inhibitor

Abstract

Background: Epilepsy is a prevalent neurological illness in humans, characterised by excessive transient neuronal discharges that lead to uncontrollable seizures, affecting about 60 million individuals globally. If untreated, it is linked to gradually deteriorating cognition and function, cerebral damage, and further neurological abnormalities. While epilepsy may often be well managed with antiepileptic medications (AEDs), around 20%-30% of individuals experience seizures that are refractory to existing pharmacological treatments. Consequently, the pursuit of a novel, more efficacious, and selective agent with less side effects remains a focal point of inquiry for medicinal chemists globally. Method: The purpose of the current study was to assess the efficiency of bioactive found in S. marianum seed for their inhibitory influence on carbonic anhydrase -II(CA-II) enzyme to elicit the anticonvulsant potency. The Auto Dock software used a grid-based docking algorithm to determine the bond. Result: S. marianum seed found to be effective anticonvulsant agent and effectively binds to be target protein carbonic anhydrase -II with binding energy of -7.86 & -6.43 kcal/mol for 7-O-methyl silybin and 2,3, dihydrosilybin respectively. Conclusion: The outcome of findings revealed that flavanolignan showed potent inhibitory effect on CA-II enzyme which reflects the efficacy of S. marianum seed as potent anticonvulsant agent.